Objective. Plasma concentration of asymmetric dimethylarginine (ADMA), a major endogenous inhibitor of nitric oxide synthase, is considered a novel risk factor for endothelial dysfunction associated with enhanced atherosclerosis. Coronary microcirculation abnormalities have been demonstrated in patients with early rheumatoid arthritis (ERA) without any signs or symptoms of coronary artery disease (CAD). The aim of the study was to compare the ERA and control groups with ADMA, intima-media thickness (IMT) and coronary flow reserve (CFR) levels. It assessed whether ERA patients have more cardiovascular risk (endothelial dysfunction and coronary microvascular abnormalities), and evaluated whether any difference in IMT/CFR between ERA and controls can be explained by any difference in ADMA levels between the groups. Methods. The study involved 25 ERA patients (female/male 21/4; mean age 52.04 +/- 14.05 years; disease duration </=12 months) and 25 healthy volunteers with no history or current signs of CAD or other traditional risk factors. Dipyridamole trans-thoracic stress echocardiography was preformed to evaluate CFR, and carotid ultrasound to measure the IMT of the common carotid arteries. Blood samples were obtained in order to assess ADMA levels before the patients had received any biological or non-biological DMARDs, or steroid therapy. Results. CFR was significantly reduced in the ERA patients (2.5 +/- 0.5 vs 3.5 +/- 0.8; P <0.01). In particular, 6/25 (24%) had a CFR of <2 consistent with potentially dangerous coronary flow impairment. Common carotid IMT was significantly greater in the ERA patients, although still within the normal range (0.68 +/- 0.1 vs 0.56 +/- 0.11 mm; P <0.01). There was a significant correlation between CFR and plasma ADMA levels in the ERA population (r = -0.53; P <0.01). IMT was negatively associated with CFR (P <0.05). Conclusions. Plasma ADMA levels were significantly higher in the ERA patients. A statistically significant negative effect of ADMA levels on CFR value was observed. The effect of ADMA levels on IMT is not significant.

Non invasive assessement of coronary flow reserve and ADMA levels in early rheumatoid arthritis patients / M. Turiel, F. Atzeni, L. Tomasoni, S. de Portu, L. Delfino, B.D. Bodini, M. Longhi, S. Sitia, M. Bianchi, P. Ferrario, A. Doria, V. De Gennaro Colonna, P. Sarzi Puttini. - In: RHEUMATOLOGY. - ISSN 1462-0324. - 48:7(2009), pp. 834-839. [10.1093/rheumatology/kep082]

Non invasive assessement of coronary flow reserve and ADMA levels in early rheumatoid arthritis patients

M. Turiel;V. De Gennaro Colonna;P. Sarzi Puttini
2009

Abstract

Objective. Plasma concentration of asymmetric dimethylarginine (ADMA), a major endogenous inhibitor of nitric oxide synthase, is considered a novel risk factor for endothelial dysfunction associated with enhanced atherosclerosis. Coronary microcirculation abnormalities have been demonstrated in patients with early rheumatoid arthritis (ERA) without any signs or symptoms of coronary artery disease (CAD). The aim of the study was to compare the ERA and control groups with ADMA, intima-media thickness (IMT) and coronary flow reserve (CFR) levels. It assessed whether ERA patients have more cardiovascular risk (endothelial dysfunction and coronary microvascular abnormalities), and evaluated whether any difference in IMT/CFR between ERA and controls can be explained by any difference in ADMA levels between the groups. Methods. The study involved 25 ERA patients (female/male 21/4; mean age 52.04 +/- 14.05 years; disease duration
Asymmetric dimethylarginine; Coronary artery disease; Coronary flow reserve; Rheumatoid arthritis; Trans-thoracic echocardiography
Settore MED/09 - Medicina Interna
2009
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/61411
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 90
  • ???jsp.display-item.citation.isi??? 87
social impact